PARP inhibitors: Choosing what to use in epithelial ovarian cancer
April 7, 2020
Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.
SUBSCRIBE: Print / Digital / eNewsletter
Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
